Overview of Viking Therapeutics’ Financial Performance

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. The company has not generated any revenue to date, as its drug candidates are still in clinical trials and have not yet been approved for commercial use.

During the nine months ended September 30, 2025, Viking incurred $191.5 million in research and development expenses, primarily related to conducting clinical trials for its lead drug candidate VK2735 for obesity, as well as trials for VK2809 for non-alcoholic steatohepatitis (NASH) and VK0214 for X-linked adrenoleukodystrophy (X-ALD). The company also spent $37.1 million on general and administrative expenses during this period.

Despite the significant R&D spending, Viking ended the third quarter of 2025 with a strong cash position of $714.6 million in cash, cash equivalents and short-term investments. This cash runway is expected to fund the company’s operations through at least the end of 2026.

Revenue and Profit Trends

Viking has not generated any revenue to date, as its drug candidates are still in clinical development and have not yet been approved for commercial sale. The company’s expenses have been primarily focused on research and development activities, including conducting clinical trials for its lead programs.

During the nine months ended September 30, 2025, Viking’s research and development expenses increased significantly to $191.5 million, up from $70.7 million in the same period of 2024. This 171% increase was driven by higher costs related to the ongoing Phase 3 VANQUISH trials for VK2735 in obesity, as well as increased manufacturing and other expenses for this program.

General and administrative expenses also increased, but at a more modest pace of 9.1%, rising to $37.1 million in the first nine months of 2025 compared to $34.0 million in the prior year period. This increase was primarily due to higher stock-based compensation and insurance costs.

As a result of the substantial R&D spending, Viking reported a net loss of $201.9 million for the nine months ended September 30, 2025, compared to a net loss of $74.5 million in the same period of 2024.

Strengths and Weaknesses

Strengths:

• Robust pipeline of novel drug candidates targeting large unmet medical needs in metabolic and endocrine disorders
• Positive clinical data for lead programs VK2735 (obesity) and VK2809 (NASH)
• Ample cash runway to fund operations through at least the end of 2026
• Established manufacturing partnerships to support commercial-scale production

Weaknesses:

• No revenue generated to date as drug candidates are still in clinical development
• Significant and increasing R&D expenses as the company advances multiple programs
• Reliance on external funding to finance operations, as the company has not yet achieved profitability

Outlook and Future Prospects

Viking’s future prospects hinge on the successful development and regulatory approval of its lead drug candidates. The company has made significant progress in advancing its pipeline, with several key milestones achieved in 2023 and 2024:

• Completion of the Phase 1 trial and initiation of the Phase 2 VENTURE study for VK2735 in obesity
• Positive results from the Phase 2 VENTURE study, showing statistically significant weight loss with VK2735 treatment
• Initiation of the pivotal Phase 3 VANQUISH program for VK2735 in obesity and obesity with type 2 diabetes
• Completion of the Phase 1b trial and initiation of a Phase 2 study for the oral formulation of VK2735
• Successful completion of the Phase 2b VOYAGE study for VK2809 in NASH, with positive histologic data

Looking ahead, the company’s key priorities will be to:

1. Complete enrollment and report results from the ongoing Phase 3 VANQUISH trials for VK2735 in obesity
2. Advance the oral formulation of VK2735 through Phase 2 development
3. Prepare for potential regulatory submissions and commercialization of VK2735 and VK2809, if approved
4. Explore partnership or licensing opportunities for its earlier-stage programs, such as VK0214 for X-ALD and VK5211 for muscle wasting

The successful execution of these goals will be critical for Viking to transition from a clinical-stage company to one that can generate sustainable revenue and profits. However, the company faces significant competition in its target therapeutic areas, and there are no guarantees that its drug candidates will ultimately receive regulatory approval.

Overall, Viking appears to be making solid progress in advancing its pipeline of novel metabolic and endocrine disorder therapies. The company’s strong cash position provides it with the resources to continue funding its R&D efforts. However, investors should closely monitor the company’s clinical trial results and regulatory progress, as the path to commercialization and profitability remains uncertain.